ABSTRACT
IU) with excipient disodium succinate, polysorbate 20, and sterile water for injections.
This is a recombinant human IFN
γ
composed of 143 aa and is devoid of the initial methionine (it appears that this is due to an enzyme activity of the
bacterial producer strain (Vassileva-Atanassova et al. 1999), and the Cys-TyrCys signaling sequence. It is produced in
E. coli
(see Chapter 5, Figure 5.2) and the technology is protected by a European patent 0446582 B1/4.01.1995 for France, Germany, Italy, Great Britain, and Spain and patent 2054044/24.01.1998 for Russia.
